Alex C Spyropoulos

Summary

Affiliation: Clinical Thrombosis Center
Country: USA

Publications

  1. ncbi Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin
    Alex C Spyropoulos
    Clinical Thrombosis Center, Lovelace Health Systems, Albuquerque, NM 87108, USA
    Chest 122:108-14. 2002
  2. ncbi Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption
    Alex C Spyropoulos
    Clinical Thrombosis Center, Lovelace Health Systems, 5400 Gibson Boulevard SE, Albuquerque, NM 87108, USA
    Pharmacotherapy 23:533-6. 2003
  3. ncbi Managing oral anticoagulation requires expert experience and clinical evidence
    Alex C Spyropoulos
    Lovelace Sandia Health Systems, Clinical Thrombosis Center, 5400 Gibson Blvd SE, Albuquerque, NM 87108, USA
    J Thromb Thrombolysis 21:91-4. 2006
  4. doi Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population
    Charles E Mahan
    Presbyterian Healthcare Services, University of New Mexico, Albuquerque, NM, USA
    Thromb Res 132:520-6. 2013
  5. doi Improving prevention and treatment of venous thromboembolism: clinical trial results
    Charles Mahan
    Department of Outcomes Research, New Mexico Heart Institute, University of New Mexico, Albuquerque, NM 87102, USA
    J Med Econ 15:611-22. 2012
  6. ncbi Pharmacologic therapy for the management of thrombosis: unfractionated heparin or low-molecular-weight heparin?
    Alex C Spyropoulos
    Clinical Thrombosis Center, Lovelace Sandia Health Systems, Albuquerque, New Mexico 87108, USA
    Clin Cornerstone 7:39-48. 2005
  7. ncbi A disease management protocol for outpatient perioperative bridge therapy with enoxaparin in patients requiring temporary interruption of long-term oral anticoagulation
    Alex C Spyropoulos
    Clinical Thrombosis Center, Lovelace Sandia Health Systems, Albuquerque, New Mexico 87108, USA
    Pharmacotherapy 24:649-58. 2004
  8. doi Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates
    Charles E Mahan
    New Mexico Heart Institute, University of New Mexico College of Pharmacy, Albuquerque, New Mexico 87102, USA
    Thromb Haemost 108:291-302. 2012
  9. doi Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry)
    Alex C Spyropoulos
    Lovelace Medical Center, Albuquerque, New Mexico, USA
    Am J Cardiol 102:883-9. 2008
  10. ncbi Management of venous thromboembolism in the elderly
    Alex C Spyropoulos
    Clinical Thrombosis Center, Lovelace Sandia Health Systems, Albuquerque, New Mexico 87108, USA
    Drugs Aging 23:651-71. 2006

Detail Information

Publications43

  1. ncbi Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin
    Alex C Spyropoulos
    Clinical Thrombosis Center, Lovelace Health Systems, Albuquerque, NM 87108, USA
    Chest 122:108-14. 2002
    ..Results demonstrated equivalent safety and efficacy for home care with enoxaparin with a reduction in cost. Our objective was to validate these findings in the routine practice setting of a US health maintenance organization...
  2. ncbi Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption
    Alex C Spyropoulos
    Clinical Thrombosis Center, Lovelace Health Systems, 5400 Gibson Boulevard SE, Albuquerque, NM 87108, USA
    Pharmacotherapy 23:533-6. 2003
    ..Health care providers managing patients who are receiving oral anticoagulant therapy should be aware of the maculopapular allergic reactions associated with warfarin and consider alternative treatment options such as anisindione...
  3. ncbi Managing oral anticoagulation requires expert experience and clinical evidence
    Alex C Spyropoulos
    Lovelace Sandia Health Systems, Clinical Thrombosis Center, 5400 Gibson Blvd SE, Albuquerque, NM 87108, USA
    J Thromb Thrombolysis 21:91-4. 2006
    ....
  4. doi Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population
    Charles E Mahan
    Presbyterian Healthcare Services, University of New Mexico, Albuquerque, NM, USA
    Thromb Res 132:520-6. 2013
    ..Medically ill, hospitalized patients are at increased risk for venous thromboembolism (VTE) after discharge. This study aimed to examine thromboprophylaxis patterns, risk factors, and post-discharge outcomes...
  5. doi Improving prevention and treatment of venous thromboembolism: clinical trial results
    Charles Mahan
    Department of Outcomes Research, New Mexico Heart Institute, University of New Mexico, Albuquerque, NM 87102, USA
    J Med Econ 15:611-22. 2012
    ..These improvement strategies focus on increasing the use of thromboprophylaxis, implementing existing guidelines, and improving awareness...
  6. ncbi Pharmacologic therapy for the management of thrombosis: unfractionated heparin or low-molecular-weight heparin?
    Alex C Spyropoulos
    Clinical Thrombosis Center, Lovelace Sandia Health Systems, Albuquerque, New Mexico 87108, USA
    Clin Cornerstone 7:39-48. 2005
    ..The aim of this article is to summarize efficacy, safety, and pharmacoeconomic considerations when selecting LMWH versus UFH for thrombosis management in VTE and NSTE ACS...
  7. ncbi A disease management protocol for outpatient perioperative bridge therapy with enoxaparin in patients requiring temporary interruption of long-term oral anticoagulation
    Alex C Spyropoulos
    Clinical Thrombosis Center, Lovelace Sandia Health Systems, Albuquerque, New Mexico 87108, USA
    Pharmacotherapy 24:649-58. 2004
    ..We sought to determine whether an alternate strategy of outpatient-based perioperative disease management with low-molecular-weight heparin (LMWH) as bridge therapy provides the potential for cost savings...
  8. doi Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates
    Charles E Mahan
    New Mexico Heart Institute, University of New Mexico College of Pharmacy, Albuquerque, New Mexico 87102, USA
    Thromb Haemost 108:291-302. 2012
    ..The cost models may be utilised to estimate other countries' costs or VTE-specific disease states...
  9. doi Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry)
    Alex C Spyropoulos
    Lovelace Medical Center, Albuquerque, New Mexico, USA
    Am J Cardiol 102:883-9. 2008
    ....
  10. ncbi Management of venous thromboembolism in the elderly
    Alex C Spyropoulos
    Clinical Thrombosis Center, Lovelace Sandia Health Systems, Albuquerque, New Mexico 87108, USA
    Drugs Aging 23:651-71. 2006
    ..New anticoagulants that may be of potential benefit in this patient population include fondaparinux sodium, but clinical experience of this drug in the elderly remains limited...
  11. ncbi Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patients
    Alex C Spyropoulos
    Clinical Thrombosis Center, Lovelace Sandia Health Systems, 5400 Gibson Blvd SE, Albuquerque, NM 87108, USA
    Chest 128:958-69. 2005
    ..Despite the availability of effective thromboprophylactic therapies, VTE prophylaxis continues to be underutilized in hospitalized medical patients...
  12. doi Identifying, monitoring and reducing preventable major bleeds in the hospital setting
    Deborah Caraballo
    New Mexico Heart Institute, University of New Mexico, 502 Elm Street NE, Albuquerque, NM 87102, USA
    J Thromb Thrombolysis 36:7-13. 2013
    ..Similar programs should be explored prospectively on a larger scale to reduce harm from anticoagulants in the hospital setting...
  13. ncbi Bridging of oral anticoagulation therapy for invasive procedures
    Alex C Spyropoulos
    Clinical Thrombosis Center, Lovelace Sandia Health Systems, 5400 Gibson Blvd SE, Albuquerque, NM 87108, USA
    Curr Hematol Rep 4:405-13. 2005
    ..This paper reviews these clinical data on bridging therapy and provides an evidence-based perioperative management strategy for the at-risk patient on chronic OAC...
  14. ncbi Prevention of venous thromboembolism in the cancer surgery patient
    Alex C Spyropoulos
    Clinical Thrombosis Center, Lovelace Medical Center, Albuquerque, NM 87108, USA
    Cleve Clin J Med 75:S17-26. 2008
    ..The risk-benefit profile of low-dose anticoagulant prophylaxis appears to be favorable even in many cancer patients undergoing neurosurgery, for whom pharmacologic VTE prophylaxis has been controversial because of bleeding risks...
  15. ncbi Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy
    Alex C Spyropoulos
    Clinical Thrombosis Center, Lovelace Health Systems, Albuquerque, NM 87108, USA
    Chest 125:1642-50. 2004
    ..v. UH, administered in a hospital setting, or LMWH, administered primarily in the outpatient setting using disease management guidelines...
  16. ncbi Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapy
    Alex C Spyropoulos
    Clinical Thrombosis Center, Lovelace Medical Center, Albuquerque, NM 87108, USA
    Curr Med Res Opin 22:1109-22. 2006
    ..This, however, creates a clinical dilemma, since discontinuing VKAs may place the patient at risk of thromboembolism...
  17. doi Venous thromboembolism prophylaxis with unfractionated heparin in the hospitalized medical patient: the case for thrice daily over twice daily dosing
    Charles E Mahan
    Cardinal Health Pharmacy Solutions, Lovelace Medical Center, Lovelace Rehabilitation Hospital, Lovelace Health Systems, 601 Dr Martin Luther King Jr Ave NE, Albuquerque, NM, 87102, USA
    Intern Emerg Med 5:299-306. 2010
    ..Newly published risk-assessment models may be beneficial in determining which patients would best benefit from BID UFH or TID UFH...
  18. doi Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event
    Charles E Mahan
    University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA
    Thromb Haemost 106:405-15. 2011
    ..8 to $52 billion, $6.8 to $36 billion, and $3.4 to $27 billion, respectively...
  19. doi Update in the treatment of venous thromboembolism
    David A Garcia
    Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA
    Semin Respir Crit Care Med 29:40-6. 2008
    ..In addition to presenting evidence relevant to the optimal duration of warfarin therapy, we highlight circumstances under which extended therapy with a parenteral agent such as a low molecular weight heparin might be preferable...
  20. ncbi Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations
    Alex C Spyropoulos
    Clinical Thrombosis Center, Lovelace Medical Center, 5400 Gibson Blvd, SE, Albuquerque, NM 87108, USA
    J Manag Care Pharm 13:475-86. 2007
    ..Venous thromboembolism (VTE) is a common medical condition manifested as deep vein thrombosis (DVT) or pulmonary embolism (PE). Few data exist on the total economic burden of DVT and PE...
  21. doi Venous thromboembolism pharmacy intervention management program with an active, multifaceted approach reduces preventable venous thromboembolism and increases appropriate prophylaxis
    Charles E Mahan
    University of New Mexico Health Sciences Center, College of Pharmacy, University of New Mexico, Albuquerque, NM 87131 0001, USA
    Clin Appl Thromb Hemost 18:45-58. 2012
    ..0006). In conclusion, a pharmacy-led multifaceted intervention can significantly increase the rates of appropriate prophylaxis and significantly reduce the incidence of preventable VTE in hospitalized patients...
  22. doi Brave new world: the current and future use of novel anticoagulants
    Alex C Spyropoulos
    Clinical Thrombosis Center, ABQ Health Partners, University of New Mexico Health Center College of Pharmacy, Albuquerque, NM 87102, USA
    Thromb Res 123:S29-35. 2008
    ....
  23. doi Rates of symptomatic venous thromboembolism in US surgical patients: a retrospective administrative database study
    Alex C Spyropoulos
    University of New Mexico Health Sciences Center, Albuquerque, NM, USA
    J Thromb Thrombolysis 28:458-64. 2009
    ..2-11.4), and orthopedic versus abdominal surgery (OR 1.4; 95% CI: 1.4-1.6). Patients undergoing orthopedic or abdominal surgery remain at-risk for VTE. Implementation of national performance measures may help reduce the burden of VTE...
  24. doi Antithrombotic medication use and bleeding risk in medically ill patients after hospitalization
    Charles E Mahan
    1Department of Outcomes Research, New Mexico Heart Institute, Albuquerque, NM, USA
    Clin Appl Thromb Hemost 19:504-12. 2013
    ..Hospitalized medically ill patients receiving antithrombotic medications experience increased risk of bleeding. We examined antithrombotic use, bleeding rates, and associated risk factors at 30 days post discharge...
  25. ncbi Prevention of venous thromboembolism: clinical and economic implications. Introduction
    Alex C Spyropoulos
    Clinical Thrombosis Center, Lovelace Medical Center, Albuquerque, NM 87108, USA
    Am J Health Syst Pharm 63:S3-4. 2006
  26. ncbi The clinical thrombosis center and clinical thrombologist: a new US health systems paradigm for the management of venous thromboembolic disease
    Alex C Spyropoulos
    Clinical Thrombosis Center, Lovelace Health Systems, 5400 Gibson Boulevard SE, Albuquerque, NM 87108, USA
    J Thromb Thrombolysis 15:227-32. 2003
    ....
  27. ncbi Investigational treatments of venous thromboembolism
    Alex C Spyropoulos
    Clinical Thrombosis Center, Lovelace Medical Center, 5400 Gibson Boulevard SE, Albuquerque, NM 87108, USA
    Expert Opin Investig Drugs 16:431-40. 2007
    ....
  28. ncbi Purple toes syndrome associated with warfarin therapy in a patient with antiphospholipid syndrome
    David B Talmadge
    University of New Mexico School of Medicine, Albuquerque, USA
    Pharmacotherapy 23:674-7. 2003
    ..No further complications occurred with long-term therapy. Although a rare complication of therapy, clinicians should monitor for the development of purple toes syndrome in patients taking warfarin...
  29. ncbi Outpatient-based primary and secondary thromboprophylaxis with low-molecular-weight heparin
    Alex C Spyropoulos
    Clinical Thrombosis Center, Lovelace Medical Center, Albuquerque, New Mexico 87108, USA
    Clin Appl Thromb Hemost 14:63-74. 2008
    ....
  30. ncbi Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients
    Alexander T Cohen
    Vascular Medicine, Department of Surgery, Guy s, King s and St Thomas School of Medicine, London, UK
    Thromb Haemost 94:750-9. 2005
    ..These medical conditions and risk factors are included in a risk-assessment model which is hoped will provide a simple means of assisting clinicians in deciding whether thromboprophylaxis should be used in an individual patient...
  31. ncbi Perioperative bridging interruption with heparin for the patient receiving long-term anticoagulation
    Alex C Spyropoulos
    Clinical Thrombosis Center Lovelace Medical Center Albuquerque, New Mexico 87108, USA
    Curr Opin Pulm Med 11:373-9. 2005
    ....
  32. ncbi Perioperative bridging therapy for the at-risk patient on chronic anticoagulation
    Alex C Spyropoulos
    Dis Mon 51:183-93. 2005
  33. ncbi Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization
    Michael F Bullano
    HealthCore, Inc, 800 Delaware Ave, Wilmington, DE 19801, USA
    J Manag Care Pharm 11:663-73. 2005
    ....
  34. ncbi Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting
    Vincent J Willey
    HealthCore, Inc, Wilmington, DE 19081, USA
    Clin Ther 26:1149-59. 2004
    ....
  35. pmc Management of venous thromboembolism: why not treat it at home?
    Alex C Spyropoulos
    Can Fam Physician 51:181-2, 184-5. 2005
  36. ncbi Prevention of venous thromboembolism in the orthopedic surgery patient
    Steven B Deitelzweig
    Department of Hospital Medicine, Ochsner Health System, New Orleans, LA 70121, USA
    Cleve Clin J Med 75:S27-36. 2008
    ..Extended-duration prophylaxis (for 4 to 5 weeks) is now recommended for patients undergoing hip arthroplasty or hip fracture repair. Patients undergoing knee arthroscopy do not require routine pharmacologic VTE prophylaxis...
  37. ncbi Prevention of venous thromboembolism in the hospitalized medical patient
    Amir K Jaffer
    Department of Medicine, Leonard M Miller School of Medicine, University of Miami, Miami, FL 33136, USA
    Cleve Clin J Med 75:S7-16. 2008
    ....
  38. ncbi Prevention of venous thromboembolism
    Mario Pini
    Medicina Interna II, Ospedale di Fidenza, Fidenza, Parma, Italy
    Semin Thromb Hemost 32:755-66. 2006
    ....
  39. ncbi Oral anticoagulation: preparing for change
    Edith A Nutescu
    University of Illinois at Chicago, College of Pharmacy, Chicago, Illinois, USA
    J Am Med Dir Assoc 5:2-11. 2004
    ..Further, the results of clinical trials suggest that ximelagatran may be as effective as warfarin in preventing stroke and VTE...
  40. ncbi Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin
    Thomas M Hyers
    Department of Internal Medicine, St Louis University School of Medicine, St Louis, MO, USA
    J Thromb Thrombolysis 24:225-32. 2007
    ..Home therapy in the usual practice setting should achieve substantial overall cost savings in the treatment of DVT...
  41. ncbi Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism
    Victor F Tapson
    Division of Pulmonary and Critical Care, Box 31175, Room 351 Bell Building, Duke University Medical Center, Durham, NC 27710, USA
    Chest 132:936-45. 2007
    ..Our aim was to characterize the clinical practices for VTE prophylaxis in acutely ill hospitalized medical patients enrolled in the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE)...
  42. doi The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    James D Douketis
    McMaster University, Hamilton, Ontario, Canada
    Chest 133:299S-339S. 2008
    ....
  43. doi Primary prevention of venous thromboembolism in long-term care: identifying and managing the risk
    Sylvia Haas
    Institut für Experimentelle Onkologie und Therapieforschung, Universitat Munchen, Ismaninger Strasse 22, Munich, Germany
    Clin Appl Thromb Hemost 14:149-58. 2008
    ..This review addresses the role of risk assessment in the decision of when to provide prophylaxis to an individual in long-term care and highlights key management issues for those prescribed prophylaxis...